ArticleInvestigative ophthalmology & visual science2013
A cationic peptide, TAT-Cd°, inhibits herpes simplex virus type 1 ocular infection in vivo.
Article in Investigative ophthalmology & visual science, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- The Use of Free-Living Amoeba in Treating Bacterial Infections: Thermotolerant Dictyostelids Are Avirulent and Do Not Cause Keratitis in Mice.Investigative ophthalmology & visual science · 2026Article
- Engineered peptide-drug conjugate provides sustained protection of retinal ganglion cells with topical administration in rats.Journal of controlled release : official journal of the Controlled Release Society · 2023Article
- Machine learning-driven multifunctional peptide engineering for sustained ocular drug delivery.Nature communications · 2023Article
- Pathobiology and treatment of viral keratitis.Experimental eye research · 2021Review
- The Tat Protein of HIV-1 Prevents the Loss of HSV-Specific Memory Adaptive Responses and Favors the Control of Viral Reactivation.Vaccines · 2020Article
- Herpes Simplex Virus: The Hostile Guest That Takes Over Your Home.Frontiers in microbiology · 2020Review
- A Novel, Broad-Acting Peptide Inhibitor of Double-Stranded DNA Virus Gene Expression and Replication.Frontiers in microbiology · 2020Article
- Current and Emerging Therapies for Ocular Herpes Simplex Virus Type-1 Infections.Microorganisms · 2019Review
- Antiviral peptides as promising therapeutic drugs.Cellular and molecular life sciences : CMLS · 2019Review
- A Mouse Model of Multi-Drug ResistantJournal of ocular biology · 2016Article
- Genital Herpes: Insights into Sexually Transmitted Infectious Disease.Microbial cell (Graz, Austria) · 2016Review
- Cell entry mechanisms of HSV: what we have learned in recent years.Future virology · 2015Article
- Peptide therapeutics for treating ocular surface infections.Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics · 2014Review
- Inhibition of ataxia telangiectasia mutated (ATM) kinase suppresses herpes simplex virus type 1 (HSV-1) keratitis.Investigative ophthalmology & visual science · 2014Article
- The antimicrobial agent C31G is effective for therapy for HSV-1 ocular keratitis in the rabbit eye model.Antiviral research · 2013Article
- An investigative peptide-acyclovir combination to control herpes simplex virus type 1 ocular infection.Investigative ophthalmology & visual science · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
purposeTo test the in vivo activity of a peptide derived from the protein transducing domain of the human immunodeficiency virus (HIV) Tat protein, TAT-Cd°, in a murine herpes simplex type 1 (HSV-1) keratitis model.
methodsthe efficacy of TAT-CD° was assessed in a postinfection treatment model with different concentrations (1 mg/mL, 0.1 mg/mL, 0.01 mg/mL) of the peptide in one of four delivery vehicles: artificial tears, PBS, methylcellulose, and aquaphor cream. Treatment began within 4 or 24 hours postinfection. Viral titers in the tear film were determined by plaque assay.
resultsTAT-Cd° reduced the severity of keratitis in all of the delivery vehicles tested when treatment started, 4 hours postinfection. Peptide in the tears or PBS delivery vehicle had the most significant reduction in disease severity and delayed the onset of vascularization and stromal keratitis. The percentage of mice presenting with disease was also significantly reduced and viral titers were reduced by 1 log at 24 hours postinfection in mice treated with 1 mg/mL TAT-Cd°, suggesting that inhibiting replication early is sufficient to achieve clinical effects. Lower concentrations were not effective and delaying treatment by 24 hours was also not effective.
conclusionsThis study shows that TAT-Cd° is an effective antiviral against HSV-1 strain KOS when applied shortly postinfection and that aqueous-based formulations are more suitable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.